Loading
A phase 2 trial of Plitidepsin in Liposarcoma, run by Institut Bergonié, recorded as terminated on the registry.
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial is a phase 2 interventional study registered as NCT01876043 by Institut Bergonié, with 24 participants recorded, started 2012-02 and due to reach its primary completion in 2015-04. Interventions recorded: plitidepsin. Conditions recorded: Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma.
Linked to the drug Plitidepsin because the registry names it among its interventions and Liposarcoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
24 enrolled.
95% CI 20.9 to 60.1; Figures from the ClinicalTrials.gov results section (first posted 2019-11-12), not from a publication
Source95% CI 1.4 to 2.6; Figures from the ClinicalTrials.gov results section (first posted 2019-11-12), not from a publication
SourceThe full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Plitidepsin and the tag pipeline.
Shares Plitidepsin and the tag pipeline.
Shares Liposarcoma and the tag pipeline.
Shares Liposarcoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/